SCHEDULE: Cormorant's Chen Bihua Discloses MoonLake Stake
Beneficial Ownership Disclosure
Bihua Chen, general partner of Cormorant Asset Management, LP, reported a 3.14% beneficial ownership stake in MoonLake Immunotherapeutics' Class A Ordinary Shares.
Summary
- Bihua Chen, a U.S. citizen, reported beneficial ownership of 1,994,173 Class A Ordinary Shares of MoonLake Immunotherapeutics.
- This ownership represents 3.14% of the Class A Ordinary Shares outstanding.
- The shares are held for the benefit of investment funds managed by Cormorant Asset Management, LP, where Bihua Chen serves as the general partner.
- The reporting person has shared voting power and shared dispositive power over all 1,994,173 shares.
- The percentage of class is calculated based on 63,501,402 Class A Ordinary Shares outstanding as of August 1, 2025, as stated in MoonLake Immunotherapeutics' Form 10-Q for the quarter ended June 30, 2025.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership and does not inherently convey positive or negative sentiment about the company's operational or financial performance. It is a factual report of an investment position.
Positives
- A significant institutional investor, Cormorant Asset Management, LP, through its general partner Bihua Chen, maintains a notable stake in MoonLake Immunotherapeutics, potentially signaling confidence in the company's long-term prospects.
Risks
- The filing of this statement should not be construed as an admission that the Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares reported herein.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding MoonLake Immunotherapeutics' future performance.
Industry Context
This Schedule 13G filing indicates that a prominent investment manager, Cormorant Asset Management, LP, continues to hold a significant, though non-controlling, stake in MoonLake Immunotherapeutics. Such disclosures are common for institutional investors and provide transparency into major ownership positions within the biotechnology and pharmaceutical sectors, where specialized funds often invest in companies with promising therapeutic pipelines.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and investor confidence.
Key Dates
| Date | Description |
|---|---|
| 08/01/2025 | Date as of which 63,501,402 Class A Ordinary Shares of MoonLake Immunotherapeutics were outstanding, as reported in the Issuer's Form 10-Q. |
| 08/05/2025 | Date MoonLake Immunotherapeutics filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. |
| 09/30/2025 | Date of event which requires the filing of this statement. |
| 10/01/2025 | Date the Schedule 13G statement was signed by Chen Bihua. |
Keywords
MoonLake Immunotherapeutics, Cormorant Asset Management, Bihua Chen, Class A Ordinary Shares, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.